Compare Boston Scientific Corporation (BSX) vs CubeSmart (CUBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs CubeSmart — how do they compare? Boston Scientific Corporation trades at $43.43 (market cap $66.37B), while CubeSmart trades at $40.58 (market cap $9.17B). The key difference: Boston Scientific Corporation is far larger — about 7.2× CubeSmart's market cap, and CubeSmart pays a 5.23% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | CUBE | |
|---|---|---|
Market Cap | $66.37B | $9.17B |
Sector | Health | Real Estate |
52-Week High | $108.14 | $42.34 |
52-Week Low | $42.63 | $35.36 |
Enterprise Value | $75.94B | $12.67B |
Dividend Yield | — | 5.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
CubeSmart (CUBE) trades at $40.61, up 1.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $43.86. The stock shows solid profitability with a 28.93% net income margin and a 5.3% dividend yield, though Q2 2026 earnings are pending. Recent news highlights value comparisons with REIT peers and a scheduled Q2 earnings release on July 30, 2026.
The outlook is cautiously optimistic, supported by strong fundamentals and analyst buy ratings, but risks include high leverage with $2.99B long-term debt and sensitivity to interest rates. Earnings beats in recent quarters provide momentum, yet macroeconomic uncertainty could pressure growth. The stock presents a balanced opportunity for income-focused investors amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
